ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CTXR vs KPTI // FREE CASH FLOW YIELD

Citius Pharmaceuticals Inc. (NASDAQ) VS. Karyopharm Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: CTXR 1 — KPTI 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CTXR VS. KPTI) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CTXR KPTI SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield ACTIVE — — — TIE /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — 0.60% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 1/9 2/9 -1.00 KPTI /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 52.5 44.3 +8.20 CTXR /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $14.4M $15.0M -$654.7K KPTI /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CTXR REV KPTI REV CTXR GROSS % KPTI GROSS % CTXR FCF KPTI FCF
FY 2025 $107.9M $146.1M — — -$26.6M -$75.4M
FY 2024 $117.6M $145.2M — — -$28.2M -$127.6M
FY 2023 $102.8M $146.0M — — -$29.1M -$92.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CTXR // BETA —
KPTI // BETA —